ABCL AbCellera Biologics

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

(Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on . A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit .

EN
11/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AbCellera Biologics

 PRESS RELEASE

AbCellera Reports Full Year 2024 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy,” said Carl Hansen...

 PRESS RELEASE

AbCellera to Participate at Upcoming Investor Conferences in March

VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health Care Conference, March 3-5 KeyBanc Capital Markets Healthcare Forum, March 18-19 Visit for additional information. About AbCellera Biologics Inc. (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and inter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch